Argus II is a novel healthcare technology that restores vision in RP patients. Improvements in visual acuity are expected to lead to improvements in patient self-confidence, decreasing their ...

USC and Second Sight Medical Products Inc., the developer of retinal prostheses for treating blindness, are expanding the clinical trial of an advanced retinal prosthesis into Europe. The announcement ...

The Argus II, a “bionic eye”, is intended to provide electrical stimulation of the retina to elicit visual perception in blind subjects with severe to profound retinitis pigmentosa, according to the ...

Providing us with a delightful glimpse of the future of humanity and bionic implants, Second Sight -- the developer of the first bionic eye to receive FDA approval in the US -- is currently working on ...

"Without the glasses you can't see a thing, put the glasses on you can suddenly see. You get that wow factor every time you do it." Philip Booth, 60, has had bionic eyes for the last three and a half ...

This undated product image provided by Second Sight Medical Products shows a new implantable device that takes the place of damaged cells inside the eye. The Food and Drug Administration on Thursday, ...

A new final guidance document published by the US Food and Drug Administration (FDA) recommends to sponsors methods of conducting clinical research in support of investigational medical device ...

University Hospitals Eye Institute in Cleveland has announced that it will begin offering patients the Argus II Retinal Prosthesis System, a “bionic eye” designed to treat late stage retinitis ...

Argus II Retinal Prosthesis fitted patients incurred a discounted incremental cost of 42,455 Euros in comparison to the patient given 'CAU' over the 25 years of time. Progressive improvement in the ...